Patents by Inventor Anna E. Crivici

Anna E. Crivici has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon-like peptide-2 analogs
    Patent number: 8933039
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: January 13, 2015
    Assignees: NPS Pharmaceuticals, Inc., 1149336 Ontario Inc.
    Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Glucagon-like peptide-2 analogs
    Patent number: 8846625
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 30, 2014
    Assignee: 1149336 Ontario Inc.
    Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
  • GLUCAGON-LIKE PEPTIDE-2 ANALOGS
    Publication number: 20110009320
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Application
    Filed: June 15, 2010
    Publication date: January 13, 2011
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Glucagon-like peptide-2 analogs
    Patent number: 7781401
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: August 24, 2010
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Glucagon-like peptide-2 analogs
    Publication number: 20030162703
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Application
    Filed: November 14, 2002
    Publication date: August 28, 2003
    Applicant: NPS Allelix Corporation
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner Smith
  • Antagonists of intestinotrophic GLP-2 peptides
    Publication number: 20030109449
    Abstract: Antagonists of glucagon-like peptide 2, have been identified. Their effects on the growth of gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonists of glucagon-like peptide 2.
    Type: Application
    Filed: November 18, 2002
    Publication date: June 12, 2003
    Applicant: 1149336 Ontario Inc.
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Antagonists of intestinotrophic GLP-2 peptides
    Patent number: 6489295
    Abstract: Antagonists of glucagon-like peptide 2, have been identified. Their effects on the growth of gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonists of glucagon-like peptide 2.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: December 3, 2002
    Assignee: 1149336 Ontario Inc.
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Glucagon-like peptide-2 analogs
    Publication number: 20010021767
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Application
    Filed: January 19, 2001
    Publication date: September 13, 2001
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Intestinotrophic glucagon-like peptide-2 analogs
    Patent number: 6184201
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: February 6, 2001
    Assignee: NPS Allelix Corp.
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Antagonists of intestinotrophic GLP-2 peptides
    Patent number: 5994500
    Abstract: Antagonists of glucagon-like peptide 2, have been identified. Their effects on the growth of gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonists of glucagon-like peptide 2.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: November 30, 1999
    Assignee: 1149336 Ontario Inc.
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith
  • Glucagon-like peptide-2 analogs
    Patent number: 5789379
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: August 4, 1998
    Assignees: Allelix Biopharmaceutical Inc., 1149336 Ontario Inc.
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner-Smith